CD46 and Miyoshi myopathy: Towards the objective of seeking alternative antigens that are present on MM MRD cells, we reported the preclinical results for a novel ADC targeting the cell surface complement inhibitor CD46, showing encouraging potential in MM cell line xenografts [14].